Ombitasvir/paritaprevir/ritonavir & dasabuvir ± ribavirin following protease inhibitors failure - a prospective multi-centre trial

Ombitasvir/paritaprevir/ritonavir & dasabuvir ± ribavirin following protease inhibitors failure - a prospective multi-centre trial

Abstract Background Hepatitis C virus (HCV) infection is a leading cause of chronic liver disease and hepatocellular carcinoma. Treatment with first generation protease inhibitors (PI) + peg-interferon (pegIFN) and ribavirin (RBV) achieved sustained virologic response (SVR) rates of 65–75% but was a...

Full description

Bibliographic Details
Main Authors: Liat Deutsch, Inbal Houri, Ziv Ben-Ari, Amir Shlomai, Ella Veitsman, Oranit Cohen-Ezra, Assaf Issachar, Orna Mor, Yael Gozlan, Rafael Bruck, Yoram Menachem, Shira Zelber-Sagi, Helena Katchman, Oren Shibolet
Format: Article
Language:English
Published: BMC 2020-04-01
Series:BMC Infectious Diseases
Subjects:
AbbVie 3D
Direct acting anti-viral agents
HCV
Protease inhibitors failure
Online Access:http://link.springer.com/article/10.1186/s12879-020-4921-3

Internet

http://link.springer.com/article/10.1186/s12879-020-4921-3

Similar Items